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Soil-transmitted helminths cause more than 1 billion human infections globally, mostly in the poorest
regions of the world. Control relies essentially on a limited panel of four drugs, and drug resistance might
be inescapable. Nitazoxanide, an anti-infective drug, has been shown to exert anthelmintic activity in
human clinical trials. In the present work, nitazoxanide was tested alone or combined with commercial-
ized anthelmintics on Trichuris muris, a whipworm mouse model, and Ancylostoma ceylanicum, a hook-
worm hamster model, in vitro and in vivo. IC50s of 61 and 12.87 lg/ml were achieved with
nitazoxanide on T. muris third-stage larvae (L3) and adult worms in vitro, respectively. An IC50 of
61 lg/ml was obtained exposing A. ceylanicum adults worms to nitazoxanide, whereas A. ceylanicum
L3 were not affected. Using scanning electron microscopy, the tegument of adult T. muris appeared
unchanged following nitazoxanide treatment, whereas swellings were seen on the tegument of the ante-
rior region of half of the A. ceylanicum specimen analyzed. Synergism was observed in vitrowhen nitazox-
anide was combined with levamisole or ivermectin on T. muris adult worms, and when combined with
levamisole, pyrantel pamoate, or ivermectin on A. ceylanicum adult worms. In T. muris-infected mice, oral
nitazoxanide achieved worm burden reductions of 56.09% and 17.37% following a single dose of 100 mg/
kg and three doses of 50 mg/kg, respectively. None of the tested drug combinations displayed activity on
T. muris in vivo. In A. ceylanicum-infected hamsters, no effect was observed for oral nitazoxanide alone,
and none of the tested combinations reached the threshold for additive effect. In conclusion, nitazoxanide
failed to demonstrate promising activity against T. muris and A. ceylanicum in vivo, regardless whether
tested as monotherapy or combined with standard drugs. Reasons for the discrepancy of these ﬁndings
compared to results obtained in clinical trials remain to be elucidated.
 2012 Australian Society for Parasitology Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction (Bethony et al., 2006; Mascarini-Serra, 2011). The arsenal ofSoil-transmitted helminths (STH) are parasitic intestinal nema-
todes affecting more than one billion people worldwide (de Silva
et al., 2003; Bethony et al., 2006; Hotez et al., 2008). The diseases
caused by STHs belong to the so-called neglected tropical diseases,
because they receive only a small percentage (<1%) of global re-
search funding (de Silva et al., 2003; Bethony et al., 2006; Hotez
et al., 2007). Pre-school and school-aged children, pregnant women
and fetuses are most vulnerable and may suffer profound morbid-
ities, including anemia, growth impairment and mental retardation
(Bethony et al., 2006; Hotez et al., 2007). The current global ap-
proach to control helminth infections is based on chemotherapy,
mainly administered in the frame of school deworming campaignsPublished by Elsevier Ltd.
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r).
Open acavailable drugs for the treatment of STH infections is limited:
albendazole, mebendazole, levamisole, and pyrantel pamoate are
recommended by the World Health Organization (WHO, 2011).
Almost all human anthelmintics were originally developed for vet-
erinary needs and have not been optimized for human use (Geary
et al. 2010). This is reﬂected in low cure rates, in particular when
single oral doses are administered against Trichuris trichiura infec-
tions (Keiser and Utzinger, 2008, 2010).
In addition, anthelmintic resistance is widespread among nem-
atodes of livestock as a consequence of frequent drug administra-
tion of the same class of compounds over long periods (Geerts
et al., 1997; Wolstenholme et al., 2004). Though there is no conclu-
sive evidence of anthelmintic resistance in humans, there is an ur-
gent need to develop backup drugs. However, despite the large
global burden of human STH (Bethony et al., 2006), few efforts
have been made to discover and develop novel nematocidal drug
candidates (Keiser and Utzinger, 2010; Olliaro et al., 2011). In addi-
tion to the discovery and development of novel antiparasitic drugs,
combination chemotherapy is a powerful strategy to slow emer-
gence of drug resistance (Barnes et al., 1995; Nyunt and Plowe,cess under CC BY-NC-ND license.
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have to be explored.
Nitazoxanide, ﬁrst described in the 1980s, is a broad-spectrum
thiazolide compound with anthelmintic, antiprotozoal and antivi-
ral properties (Rossignol and Maisonneuve, 1984; Rossignol and
Stachulski, 1999; Hemphill et al., 2006). More recently, it has been
demonstrated that nitazoxanide exhibits also activity when
administered in multiple doses against a number of geohelminths,
including Ascaris lumbricoides and T. trichiura (Fox and Saravolatz,
2005; Anderson and Curran, 2007; van den Enden, 2009). Nitazox-
anide was therefore listed as a potential drug development candi-
date eligible for rapid transitioning into development for human
STH infections (Olliaro et al., 2011).
Hence, it was our aim to further characterize the potential of
nitazoxanide as nematocidal drug using the parasite-rodent mod-
els Trichuris muris and the hookworm Ancylostoma ceylanicum. In
vitro, the worms’ viability of larvae and adult worms was deter-
mined following incubation with nitazoxanide using the motility
assay (Stepek et al., 2006; Kopp et al., 2008; Silbereisen et al.,
2011). Scanning-electron microscopy pictures are presented to
underscore our results. In vivo, T. muris-infected mice and A. ceylan-
icum-infected hamsters were treated with single or multiple doses
of nitazoxanide. In addition, the drug was combined in vitro with
each standard drug (albendazole, mebendazole, levamisole, pyran-
tel pamoate) as well as ivermectin and the interaction of each com-
bination was assessed. Synergistic combinations were tested
in vivo.2. Materials and methods
2.1. Drugs
Nitazoxanide was kindly provided from Laboratoria Wolfs
(Zwijndrecht, Belgium) and for in vitro assays a drug stock (5–
10 mg/ml) was prepared in 100% DMSO (Sigma–Aldrich, Buchs,
Switzerland) and stored at 4 C. For in vivo assays, a nitazoxanide
suspension in 10% [Tween 80, 80% EtOH (70:30 v/v, Fluka)] and
90% dH2O was prepared before treatment. Albendazole, mebenda-
zole, pyrantel pamoate and ivermectin were purchased from Sig-
ma–Aldrich, and levamisole hydrochloride, from Fluka (Buchs,
Switzerland), and prepared in the same way.
2.2. Animals and parasites
Three to ﬁve week-old female C57BL/10 mice and 3 week-old
male Syrian golden hamsters were purchased from Charles River
(Blackthorn, UK and Sulzfeld, Germany, respectively). Before infec-
tion, animals were allowed to acclimatize for 1 week, kept in
groups of 10 (mice) or 5 (hamsters) in macrolon cages with free ac-
cess to water and rodent food pellets (Rodent Blox from Eberle NA-
FAG, Gossau, Switzerland) and with a 12 h light/dark cycle
according to Swiss cantonal and national regulations (Permission
No. 2070). T. muriswas obtained from Prof. J.M. Behnke (University
of Nottingham) and Prof. H. Mehlhorn (University of Düsseldorf) in
2010 and A. ceylanicum was provided by Prof. J.M. Behnke (Univer-
sity of Nottingham), in 2009.
2.3. Parasites and infections
The T. muris and A. ceylanicum rodent models have been de-
scribed elsewhere (Tritten et al., 2011). Mice and hamsters were
immunosuppressed with dexamethasone in the drinking water
(4 mg/l and 1 mg/ml, respectively, dexamethasone-water soluble,
Sigma–Aldrich) from 2 days before infection until 2 days before
treatment (Campbell, 1968; Wakelin, 1970). Mice received an oraldose of 200 embryonated T. muris eggs (Wakelin, 1970; Stepek
et al., 2006). Hamsters were infected orally with 150 A. ceylanicum
third-stage larvae (L3) (Ray and Bhopale, 1972; Garside and
Behnke, 1989). Hamsters assigned to in vivo studies were not
immunosuppressed and were infected with 300 L3.
2.4. In vitro studies
2.4.1. T. muris
2.4.1.1. Activity of nitazoxanide on L3 and adults. In vitro studies
with T. muris were performed as described previously (Stepek
et al., 2006; Silbereisen et al., 2011). Brieﬂy, L3 (on day 20 p.i.)
and adult worms (from day 35 p.i. onwards) were isolated from
the intestines of mice (Stepek et al., 2006). Three to four parasites
were incubated for 72 h at 37 C, 5% CO2 in 100 ll (96-well) or
500 ll (48-well) RPMI medium [10.44 g RPMI 1640 (Gibco, Basel,
Switzerland), 5 g albumax H (Gibco), 5.94 g HEPES (Sigma–Al-
drich), 2.1 g sodium bicarbonate (Sigma–Aldrich), in 1 l dH2O sup-
plemented with 5% v/v amphotericin B (250 lg/ml, Sigma–Aldrich)
and 1% v/v penicillin–streptomycin (10,000 U/ml penicil-
lin + 10 mg/ml streptomycin, Sigma–Aldrich), in the presence of
12.5, 25, 50, 100 and 200 lg/ml (adults) and 50, 100 and 200 lg/
ml (L3) nitazoxanide (Fonseca-Salamanca et al., 2003). Parasite
motility was evaluated microscopically (Carl Zeiss, Germany, mag-
niﬁcation 20–80) 24, 48 and 72 h after start of incubation, using a
motility scale from 3 (normal motility, full viability) to 0 (no move-
ment, death). As controls, 3 worms incubated in the highest DMSO
concentration used in the assays and in RPMI medium alone were
used (2% v/v).
2.4.1.2. Combination chemotherapy studies. Nitazoxanide was
combined with albendazole, mebendazole, levamisole, pyrantel
pamoate or ivermectin using a constant dose ratio (DR) based
on estimated IC50 values: nitazoxanide = 25 lg/ml, albendazole =
200 lg/ml, mebendazole and ivermectin = 100 lg/ml, levamisole
and pyrantel pamoate = 50 lg/ml (Tritten et al., 2011 and unpub-
lished work). Three to four adult T. muris were incubated in four
different concentrations of each drug combination (2xIC50 : 2xIC50,
IC50 : IC50, 0.5xIC50 : 0.5xIC50 and 0.25xIC50 : 0.25xIC50).
2.4.2. A. ceylanicum
2.4.2.1. Activity of nitazoxanide on L3 and adults. In vitro studies
with A. ceylanicum were conducted as described recently (Tritten
et al., 2011, 2012). Brieﬂy, 30 L3 per well (96-well plates, Costar)
were incubated for 72 h at room-temperature in 200 ll HBSS med-
ium (Gibco) supplemented with 10% v/v amphotericin B (250 lg/
ml, Sigma–Aldrich) and 1% v/v penicillin–streptomycin (10,000 U/
ml penicillin + 10 mg/ml streptomycin, Sigma–Aldrich) containing
drug concentrations ranging from 0.01 to 100 lg/ml. The larval
survival (ability to move, alive; no movement, death) was investi-
gated microscopically (magniﬁcation 20) following addition of
hot water (80 C) and exposure to microscope light. Drug suscep-
tibilities of adult worms (obtained by dissection of hamster intes-
tines) were tested in 48-well plates (Costar) with 2–3 worms per
well and 1 ml HBSS medium supplemented with antibiotics and
10% v/v fetal calf serum (Connectorate AG, Switzerland) in the
presence of 0.01–100 lg/ml of the drugs at 37 C, 5% CO2 for
72 h. The motility was determined microscopically (magniﬁcation
20) using a viability scale ranging from 2 (normal motility, full
viability) to 0 (no movement, death). Based on the motility values
obtained with L3 and adults IC50s were calculated. Control worms
were incubated in the highest DMSO concentration used in the test
(2% v/v). Assays were conducted in duplicate at least twice.
2.4.2.2. Combination chemotherapy studies. L3 and adult worms
were incubated with nitazoxanide combined with albendazole,
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scribed recently (Tritten et al., 2012). Brieﬂy, 50 ll of the individual
drug solutions were added to each well and serially diluted, in or-
der to have ﬁnal concentrations ranging from 2IC50 to 0.25IC50
for each drug. IC50 values of the partner drugs have been presented
recently (Tritten et al., 2011, 2012). The IC50 values of mebendazole
were determined in the present work. The assay was conducted at
least twice in duplicate and the interaction of each combination
was assessed.
2.4.2.3. Ovicidal activity of nitazoxanide. The ovicidal activity of
nitazoxanide was assessed following a modiﬁed protocol based
on Fonseca-Salamanca et al. (2003) and Tritten et al. (2011).
Brieﬂy, in 48-well plates (Costar), 50 eggs were incubated in
dH2O containing 10 lg/ml nitazoxanide. After 24 h exposure at
room-temperature, 20 eggs per well were examined microscopi-
cally (magniﬁcation 80–160) for embryonation, and after 48 h,
for hatching. Control wells contained the same amount of DMSO
used as in the drug assay (0.2% v/v). The assay was conducted in
quadruplicate.
2.4.3. Scanning electron microscopy studies
The effect of nitazoxanide on the tegument of adult T. muris and
A. ceylanicum was observed using scanning electron microscopy
(SEM). After 24 h of incubation with the drug, both parasites were
ﬁxed in 2.5% glutaraldehyde (Alfa Aesar GmbH, Germany) in PBS
(pH 7.4) for approximately 24 h at room-temperature. Each worm
was washed three times in PBS and stored in 500 ll PBS at 4 C un-
til use. Before SEM examination, the samples were dehydrated
stepwise for 10 min in 500 ll ascending ethanol concentrations
(30%, 50%, 70% and >96% (ethanol absolute, Merck)), at room-tem-
perature and kept in 500 ll 96% ethanol at 4 C (Manneck et al.,
2010). Finally, the worms were dried to critical point (Bal-tec
CPD 030), ﬁxed on aluminum stubs and sputter coated with
20 nm gold particles. SEM pictures were acquired with a high-res-
olution scanning electron microscope (Phillips XL30 ESEM and
Nova™ Nano SEM 230) at an accelerating voltage of 5 kV.
2.5. In vivo studies
2.5.1. T. muris
2.5.1.1. Nitazoxanide monotherapy. In vivo studies with T. muris-in-
fected mice were conducted as described recently (Tritten et al.,
2011). Brieﬂy, each mouse was checked for presence of infection
(presence of eggs in the stools) on day 41 p.i. Groups of 3–4 in-
fected animals were assigned to treatment (100, 300, 600 mg/kg
single dose or 50 mg/kg nitazoxanide per day over 3 days (Fonse-
ca-Salamanca et al., 2003) or control groups (4 animals each). Ex-
pelled worms present in the mouse stools (collected up to 72 h
after treatment) were counted. On day 7 post-treatment, the mice
were sacriﬁced and the remaining worms in the gut counted. The
worm burden reduction (WBR) as well as the worm expulsion rate
(WER) were calculated for each treatment (Rajasekariah et al.,
1991).
2.5.1.2. Combination chemotherapy studies. Combinations found
synergistic at IC50 in vitro were tested in vivo. Drugs were com-
bined using a constant ratio based on the approximate ED50 values
of the partner drugs (unpublished data). Nitazoxanide (100 mg/kg,
best-performing dose) was combined with levamisole (46 mg/kg)
or ivermectin (4 mg/kg). Drug effects were analyzed as described
above.
2.5.2. A. ceylanicum
2.5.2.1. Nitazoxanide monotherapy. The A. ceylanicum experiments
were carried out as summarized recently (Tritten et al., 2011).Brieﬂy, the fecal egg burden was established on days 21 and
22 p.i. and hamsters were assigned to equally balanced treatment
groups accordingly (3–4 animals each). Hamsters were treated
with a single oral dose of 10 mg/kg nitazoxanide on day 23 p.i. Four
animals were left untreated and served as controls. Stools were
collected from each hamster over a period of 48 h after treatment
and carefully searched for worms. Hamsters were sacriﬁced on day
7 post-treatment and the remaining worms counted. WBR and
WER were calculated (Rajasekariah et al., 1986; Xue et al., 2005;
Tritten et al., 2011).
2.5.2.2. Combination chemotherapy studies. Combinations behaving
synergistically at IC50 in vitro were tested in vivo. Nitazoxanide
(10 mg/kg) was combined with levamisole, pyrantel pamoate or
ivermectin. Approximate ED50 values were calculated for the part-
ner drugs (levamisole: 10 mg/kg (Tritten et al., 2012), pyrantel
pamoate: 10 mg/kg, ivermectin: 0.04 mg/kg (unpublished data)).
2.6. Statistical analyses
The average of motility scores was calculated for each concen-
tration, converted into a percentage value and normalized to the
control, using Microsoft Excel 2010. Differences in the motility
of drug-treated and control worms and ovicidal activity were
examined using the Fisher’s exact test, with a signiﬁcance level
of 0.05, using Microsoft Excel 2010 or StatsDirect (version 2.4.5;
StatsDirect Ltd., Cheshire, UK). IC50 values were expressed based
on the median effect principle using the CompuSyn software (ver-
sion 1.0), where a ﬁtted curve is modeled and r is the linear corre-
lation coefﬁcient of the median-effect plot, indicating the goodness
of ﬁt (Chou, 1976). Combination indices (CI) were calculated with
CompuSyn. Brieﬂy, the behavior of a combination was categorized
according to the following scale: CI > 1: antagonism; CI = 1: addi-
tive effect; CI < 1: synergism (Chou, 1976). Worm burden reduc-
tions were determined by comparing the mean number of adult
worms in the intestine of a treated group with the mean number
of the control group, in Microsoft Excel 2010. Worm expulsion
rates were calculated by dividing worm output of a treatment
group by the total worm burden, using Microsoft Excel 2010.
ED50s were calculated based on the WBRs, using CompuSyn. The
Kruskal–Wallis test (multiple doses against control) or the
Mann–Whitney U test (single dose against control) was used to as-
sess the statistical signiﬁcance of the WBRs, using StatsDirect.3. Results
3.1. In vitro studies
3.1.1. T. muris
3.1.1.1. Activity of nitazoxanide on L3 and adults. Nitazoxanide had a
marked effect on both T. muris L3 and adult worms. L3 were either
dead (200, 50 lg/ml) or showed a large reduction in viability
(reduction >85%, all P < 0.001) following incubation with 100 lg/
ml for 72 h (data not shown). The temporal effect of ﬁve different
concentrations of nitazoxanide on the viability of adult T. muris is
presented in Fig. 1. Adults incubated in nitazoxanide (200, 100,
50 lg/ml) were markedly affected (>65% viability reduction) 24 h
post-incubation (all P < 0.001). At 200 lg/ml adult T. muris were
dead after 48 h (P < 0.001). After 72 h, adult T. muriswere still alive
when exposed to 100 and 50 lg/ml nitazoxanide, but showed little
movement (motility <1, all P < 0.001). Nitazoxanide concentrations
of 25 lg/ml reduced viability by 44% (P < 0.03), whereas a concen-
tration of 12.5 lg/ml of the drug had no effect on adult worms
(P > 0.05) 72 h post-incubation. All control worms showed normal
movement (motility = 3) during the entire incubation period
Fig. 1. In vitro effect of nitazoxanide on adult T. muris worms after 24, 48 and 72 h
of incubation with 12.5, 25, 50, 100 and 200 lg/ml. NTZ = nitazoxanide. Motility
scale: 3 = normal motility; 2 = low motility; 1 = very low motility; 0 = dead.
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were calculated for L3 and adults, respectively. IC50s are summa-
rized in Table 1.3.1.1.2. Combination chemotherapy studies. Five different drug com-
binationswere tested against adult T. muris. A synergistic effect was
observed with the combination of nitazoxanide and ivermectin
(CI = 0.63, DR = 1:4). A nearly additive effect was calculated for nita-
zoxanide combinedwith levamisole (CI = 0.99, DR = 1:2). For exam-
ple, even the lowest concentrations of nitazoxanide (6.25 lg/ml)
and levamisole (25 lg/ml) tested reduced the viability of theworms
to less than 50% (motility: 1.29 ± 0.49, P < 0.001). The combinations
of nitazoxanide–pyrantel pamoate (DR = 1:2), nitazoxanide–alben-
dazole (DR = 1:8), and nitazoxanide–mebendazole (DR = 1:4) re-
vealed antagonistic effects (CI = 4.94, 2.64 and 2.28, respectively).
Normal viability was observed with control worms (motility = 3)
until the end of the experiment (72 h).3.1.2. A. ceylanicum
3.1.2.1. Activity of nitazoxanide on L3, adults and eggs. No effect on
L3 motility was observed when A. ceylanicum were incubated with
100 lg/ml nitazoxanide (P = 0.50) for 72 h. As many as 74.2% of lar-
vae survived in the presence of 10 lg/ml (P < 0.001), 81.1% in 1 lg/
ml (P < 0.001) and 93.3% in 0.1 lg/ml (P = 0.059) (Fig. 2). An IC50 of
>100 lg/ml (r not determined) was calculated for L3 (Table 1).
Adult worms were very sensitive to nitazoxanide. A concentra-
tion of 100 lg/ml killed all adult worms (P < 0.001). At 10 lg/ml,
the worms showed strongly reduced viability (motility of 0.8;
P = 0.028). The lower nitazoxanide concentrations of 1 and
0.1 lg/ml only slightly decreased adult hookworm motilityTable 1
Median effect doses (IC50s) of nitazoxanide, mebendazole and ivermectin and combinatio
Drug IC50s (r) (lg/ml)
T. muris
L3
Nitazoxanide 0.27 (0.92)
Mebendazole n.d.
CI at IC50 nitazoxanide–albendazole n.d.
CI at IC50 nitazoxanide–mebendazole n.d.
CI at IC50 nitazoxanide–levamisole n.d.
CI at IC50 nitazoxanide–pyrantel pamoate n.d.
CI at IC50 nitazoxanide–ivermectin n.d.
IC50s were calculated 72 h post incubation; r = linear correlation coefﬁcient of the media
not determined.(motility values of 1.6 and 1.75, respectively (both P > 0.05)). An
IC50 of 0.74 lg/ml (r = 0.93) was determined (Table 1).
For comparison, control worms incubated with DMSO showed
an average motility of 1.93. No reduction in egg embryonation
and hatching was observed in nitazoxanide-treated wells, com-
pared to the controls (both P = 0.50).
3.1.2.2. Combination chemotherapy studies. Nitazoxanide combined
with albendazole resulted in a CI of 1.90, suggesting an antagonis-
tic behavior against adult worms in vitro (Table 1). An additive ef-
fect (CI = 1.0) was observed with the nitazoxanide–mebendazole
combination. Nitazoxanide combined with levamisole, pyrantel
pamoate or ivermectin showed synergism, with CIs of 0.32, 0.14
and 0.69, respectively.
3.1.3. Scanning electron microscopy studies
3.1.3.1. T. muris. Nitazoxanide treated T. muris (200 lg/ml) and
control worms were examined after incubation for 24 h (Fig. 3A–
D). According to our in vitro studies worms are already strongly af-
fected at this examination point.
No tegumental changes were observed with treated worms
(Fig. 3A and C) compared to controls (Fig. 3B and D) at the anterior
as well as the posterior tegument.
3.1.3.2. A. ceylanicum. In 2 out of 4 specimen, SEM revealed many
areas of swelling (knobs) in the anterior part of adult A. ceylanicum
24 h post-incubation in the presence of a lethal concentration of
100 lg/ml nitazoxanide (all worms were dead, Fig. 4A). These
structures were not observed on the tegument of control worms
that had been incubated with DMSO (Fig. 4B).
3.2. In vivo studies
3.2.1. T. muris
3.2.1.1. Nitazoxanide monotherapy. Mice were treated with single
100, 300 or 600 mg/kg nitazoxanide, or 3 doses of 50 mg/kg given
over 3 consecutive days (Table 2). The highest WBR of 56.09% was
achieved following administration of 100 mg/kg nitazoxanide.
However, a low WER of 16.23% was observed for this dose. Higher
dosages did not result in increased activity (WERs of 2.0% and 0%
andWBRs of 0% and 0%, at 300 and 600 mg/kg, respectively). Worm
burden reductions in nitazoxanide-treated mice (all single dos-
ages) were not signiﬁcant (P = 0.910). Fifty mg/kg given in multiple
doses reduced the worm burden by 17.37% (P = 0.543) and resulted
in a WER of 1.84%.
3.2.1.2. Combination chemotherapy studies. Nitazoxanide (100 mg/
kg) combined with levamisole (ED50) resulted in a moderate WER
of 33.9% and a very low WBR (0.27%) (P = 0.629). Nitazoxaniden indices of selected drug combinations on T. muris and A. ceylanicum.
A. ceylanicum
Adults L3 Adults
12.87 (0.70) >100 (n.d.) 0.74 (0.93)
n.d. 11.55 (0.87) >100 (0.87)
2.64 n.d. 1.90
2.28 n.d. 1.00
0.99 n.d. 0.32
4.94 n.d. 0.14
0.63 n.d. 0.69
n-effect plot, indicating the goodness of ﬁt. rP 0.85 indicates a satisfactory ﬁt. n.d.:
Fig. 2. Comparison of the in vitro effect of nitazoxanide on different parasite stages of A. ceylanicum. (A) L3; (B) adults. NTZ = nitazoxanide. Black bars represent incubation
with 100 lg/ml, white bars incubation with 10 lg/ml, striped bars incubation with 1 lg/ml and grey bars incubation with 0.1 lg/ml. Motility scale for adults: 2 = normal
motility; 1 = low motility; 0 = dead.
Fig. 3. SEM pictures of T. muris adults incubated for 24 h with nitazoxanide (A + C) or medium without drug (B + D). (A) Tegument of a nitazoxanide-treated worm (200 lg/
ml) and the corresponding control (B), (both magniﬁcation 1000), (C) anterior part with glands of nitazoxanide-treated worms and control (D) both at higher magniﬁcations
(3000).
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and had no effect on the WBR (P = 0.629).
3.2.2. A. ceylanicum
3.2.2.1. Nitazoxanide monotherapy. Treatment of A. ceylanicum-in-
fected hamsters with a single 10 mg/kg oral dose had no effect
on the worm burden (WER and WBR = 0%) (P = 0.857), as shown
in Table 3.3.2.2.2. Combination chemotherapy studies. Levamisole (10 mg/kg)
administered simultaneously with nitazoxanide (10 mg/kg) pro-
duced a WER of 64.29% and a low WBR of 18.02% (P = 0.80)
(Table 3). The combination nitazoxanide–pyrantel pamoate (both
10 mg/kg) moderately reduced the infection, with an observed
WER of 27.78% and a WBR of 70.27% (P = 0.60). Ivermectin
administered together with nitazoxanide (0.04 mg/kg + 10 mg/kg,
respectively) resulted in a WER of 56.34% and a WBR of 70.19%
Fig. 4. SEM pictures of A. ceylanicum adult worms. (A) Treated with nitazoxanide, anterior part showing tegumental knobs (arrow) (magniﬁcation 1000), (B) anterior part of
a control worm (magniﬁcation 1000).
Table 2
In vivo effect of nitazoxanide on T. muris, alone and in combination.
Group Dose (mg/kg) Mean number of worms (SD) Mean number of expelled worms (SD) Worm expulsion rate
(%)
Worm burden reduction (%) P-value
Control 1 – 109.5 (32.91) 0.68 (0.50) 0 – –
Control 2 – 157.5 (62.57) 0.2 (0.45) 0 – –
Control 3 – 98.33 (28.04) 0.33 (0.58) 0.34 – –
Control 4 – 56.0 (55.32) 0 (0) 0 – –
Nitazoxanide 1001 57.0 (60.55) 9.25 (13.20) 16.23 56.09 0.910a
3003 182.5.0 (114.54) 3.66 (6.35) 2.0 0
6004 87.0 (74.48) 0 (0) 0 0
50  32 122.0 (32.84) 2.25 (3.30) 1.84 17.37 0.543b
Control 5 – 91.25 (23.73) 0 (0) 0 – –
Nitazoxanide–
levamisole
100 + 465 137.66 (99.80) 46.67 (37.16) 33.90 0.27 0.629b
Nitazoxanide–
ivermectin
100 + 45 185.33 (150.51) 46.33 (21.96) 25.0 0 0.629b
Numbers in superscript refer to the corresponding control group.
a Kruskal–Wallis test comparing the median of the worm burdens of control and treated mice.
b Mann–Whitney U test comparing the median of the worm burdens of control and treated mice.
Table 3
In vivo effect of nitazoxanide on A. ceylanicum, alone and in combination.
Group Dose (mg/
kg)
Mean number of worms
(SD)
Mean number of expelled worms
(SD)
Worm expulsion rate
(%)
Worm burden
reduction (%)
P-
valuea
Control 1 – 13.8 (8.0) 0 (0) 0 – –
Nitazoxanide 101 17.8 (2.10) 0 (0) 0 0 0.857
Control 2 – 18.5 (23.33) 0 (0) 0 – –
Control 3 – 26.0 (4.24) 0 (0) 0 – –
Nitazoxanide–levamisole 10 + 102 9.33 (8.10) 6.0 (4.60) 64.29 18.02 0.80
Nitazoxanide–pyrantel
pamoate
10 + 102 18.0 (20.10) 5.0 (2.70) 27.78 70.27 0.60
Nitazoxanide–ivermectin 10 + 0.043 17.75 (15.80) 10 (5.89) 56.34 70.19 0.80
Numbers in superscript refer to the corresponding control group.
a Mann–Whitney U test comparing the median of the worm burdens of control and treated hamsters.
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higher efﬁcacy than levamisole, pyrantel pamoate or ivermectin
alone (Tritten et al., 2011).4. Discussion
Worldwide, about 3 billion people are estimated to be at risk of
STH infections (de Silva et al., 2003). Sincewe rely on only four drugs
for the treatment of STH infections, many of which are suboptimal,
new therapies and/or drug combinations are urgently needed.Nitazoxanide was ﬁrst described for its cestocidal properties, la-
ter for anti-protozoal and anti-viral activities and recently for its po-
tential against different nematodes and trematodes (Rossignol and
Maisonneuve, 1984; Anderson and Curran, 2007; van den Enden,
2009). Among the helminths, Fasciola hepatica (Favennec et al.,
2003),A. lumbricoides, T. trichiura,Ancylostoma duodenale, Enterobius
vermicularis and Strongyloides stercoralishave been shown in clinical
trials tobe affectedby treatmentwithnitazoxanide (RomeroCabello
et al., 1997; Abaza et al., 1998; Ortiz et al., 2002).
In the present investigation, we evaluated the activity of nita-
zoxanide against T. muris and A. ceylanicum, two well-established
104 L. Tritten et al. / International Journal for Parasitology: Drugs and Drug Resistance 2 (2012) 98–105parasite-rodent models that mimic human soil-transmitted hel-
minthiases, in vitro and in vivo. With minor differences in sensitiv-
ity, both T. muris stages were markedly affected by nitazoxanide
in vitro. Adult worms incubated with 50, 100 and 200 lg/ml nita-
zoxanide showed signiﬁcantly decreased viabilities and at the
highest concentration (200 lg/ml) tested, all T. muris died. Addi-
tionally, nitazoxanide signiﬁcantly decreased the motility of L3.
On the other hand, differing stage susceptibilities were observed
for hookworms; A. ceylanicum L3 were only moderately affected
by nitazoxanide in vitro, while adult worms were killed only at
the highest tested nitazoxanide dose. The hookworm third stage
larva is a developmentally arrested non-feeding stage, where phys-
iological processes and exchanges with the environment are
greatly reduced (Cassada and Russell, 1975; O’Riordan and Burnell,
1989, 1990; Burnell et al., 2005). Hence, if nitazoxanide requires
ingestion by the worm to exert its anthelmintic activity, or if the
target enzymes are missing at this stage, it would not be surprising
that A. ceylanicum L3 would remain unaffected by the drug. Simi-
larly, monepantel only affected adult A. ceylanicum and showed a
low activity on L3 (Tritten et al., 2011).
To our knowledge, we have investigated the effect of nitazoxa-
nide on A. ceylanicum and T. muris using SEM for the ﬁrst time. SEM
did not identify any marked effect of nitazoxanide (200 lg/ml) on
the T. muris adult worm tegument compared to controls. However,
SEM revealed small tegumental knobs in the anterior region of half
of the treated A. ceylanicum specimen, possibly associated with
exposure to the drug.
Note that, in mice, nitazoxanide is rapidly transformed and only
tizoxanide, the active metabolite, is measurable in plasma. How-
ever, in vitro, nitazoxanide and tizoxanide have shown similar
activities against a wide range of protozoa and bacteria (Stettler
et al., 2004; Anderson and Curran, 2007). Surprisingly, however,
nitazoxanide administered in vivo had no signiﬁcant impact on
the helminths infections studied, regardless of the dose and treat-
ment schedule. It is striking that the greatest activity against
T. muris (WER andWBR of 16% and 56%, respectively) was observed
with the lowest dose (100 mg/kg) of nitazoxanide tested. It is also
worth mentioning that again a pronounced inter-individual vari-
ability was noted treating mice at this dose, as the worm burden
reduction was 0% in half of the mice and in others high WBRs
and WERs were observed.
An interaction between host immunity and the effect of nita-
zoxanide has been reported by Cabada and White (2010), who
found that the drug lacked efﬁcacy against cryptosporidiosis in
immunocompromised patients. Since the T. muris-infected mice
were immunosuppressed until 2 days before treatment (and the
mice immune status had therefore not reached normality yet at
the time treatment was administered), this could have induced
the observed unresponsiveness to the drug. However, this hypoth-
esis is not supported by the fact that also in A. ceylanicum-infected
hamsters which had not been immunosuppressed, no drug effect
was observed. In addition, nitazoxanide achieved consistent oocyst
shedding inhibition in an immunosuppressed rat model of crypto-
sporidiasis (Li et al., 2003).
The low activity of nitazoxanide observed in our study in vivo is
in contrast to ﬁndings from human clinical trials. High cure and
egg reduction rates were observed against A. lumbricoides, A. duo-
denale and T. trichiura, comparing favorably to albendazole, the
current drug of choice (Romero Cabello et al., 1997; Abaza et al.,
1998; Ortiz et al., 2002).
The striking differences between our in vivo studies and human
clinical trial results cannot be explained at the moment. In proto-
zoa and anaerobic bacteria, nitazoxanide was shown to be a non-
competitive inhibitor of the pyruvate oxydoreductases (Hoffman
et al., 2007). However, evidence for this is lacking and alternative
mechanisms have been proposed (Hemphill et al., 2006; Müllerand Hemphill, 2011). It has been suggested that the activity of nita-
zoxanide is quenched in the stomach by gastric acids (pH 3), by
transforming the drug into a biologically inactive protonated form
which might be restored to the active anion by the more alkaline
pH in the small intestine. In the same report, the presence of the
active anion form of nitazoxanide was revealed from pH 6 and
above (Hoffman et al., 2007). In mice, the mean intestinal pH is
<5.2, much lower than values observed in humans (pH 7.5), with
some consistent inter-individual variations (Evans et al., 1988;
McConnell et al., 2008). If the proposed mode of action for nitazox-
anide also applies to helminths, the substantial intestinal pH differ-
ences between humans and rodents might explain the
unexpectedly low in vivo activity, and would make rodent models
inappropriate to test drugs strongly relying on narrow intestinal
pH ranges.
To our knowledge, we have for the ﬁrst time evaluated the ef-
fect of nitazoxanide drug combinations. Though synergistic activity
was observed using combinations of nitazoxanide and standard
anthelminthic drugs in vitro, these effects could not be conﬁrmed
in vivo, possibly also because of intestinal pH incompatibilities.
In conclusion, nitazoxanide was found highly potent against
both T. muris stages tested, whereas only A. ceylanicum adult
worms were found sensitive to the drug in vitro. In both parasite-
rodent models, the drug exhibited poor efﬁcacy. Further studies
in non-rodent systems are necessary to explain the differences be-
tween our results and ﬁndings obtained in clinical trials.
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